Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lessened its holdings in Airbnb, Inc. (NASDAQ:ABNB – Free Report) by 58.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 309,717 shares of the company’s stock after selling 441,712 shares during the quarter. Amova Asset Management Americas Inc. owned 0.05% of Airbnb worth $39,080,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ABNB. Transamerica Financial Advisors LLC boosted its stake in Airbnb by 143.6% in the 4th quarter. Transamerica Financial Advisors LLC now owns 190 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. ORG Partners LLC increased its stake in Airbnb by 97.0% during the 4th quarter. ORG Partners LLC now owns 195 shares of the company’s stock valued at $26,000 after purchasing an additional 96 shares in the last quarter. Entrust Financial LLC purchased a new position in shares of Airbnb in the fourth quarter worth $27,000. Aventura Private Wealth LLC purchased a new position in shares of Airbnb in the fourth quarter worth $29,000. Finally, Meeder Asset Management Inc. lifted its stake in shares of Airbnb by 96.3% during the first quarter. Meeder Asset Management Inc. now owns 214 shares of the company’s stock worth $27,000 after buying an additional 105 shares during the period. Institutional investors and hedge funds own 80.76% of the company’s stock.

Insider Activity In related news, Director Joseph Gebbia sold 2,460 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $150.00, for a total transaction of $369,000.00. Following the sale, the director directly owned 2,595,119 shares of the company’s stock, valued at approximately $389,267,850. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kenneth I. Chenault sold 8,346 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $150.00, for a total transaction of $1,251,900.00. Following the sale, the director owned 40,879 shares in the company, valued at approximately $6,131,850. This represents a 16.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,256,652 shares of company stock worth $312,089,856 over the last 90 days. Company insiders own 27.21% of the company’s stock.

Airbnb Price Performance Shares of ABNB opened at $144.94 on Tuesday. The business’s 50-day moving average is $139.29 and its two-hundred day moving average is $134.46. The company has a market capitalization of $87.36 billion, a P/E ratio of 35.70, a P/E/G ratio of 1.56 and a beta of 1.14. Airbnb, Inc. has a fifty-two week low of $110.81 and a fifty-two week high of $150.88. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.44 and a current ratio of 1.44.

Airbnb (NASDAQ:ABNB – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.05). The company had revenue of $2.68 billion during the quarter, compared to analyst estimates of $2.62 billion. Airbnb had a net margin of 19.90% and a return on equity of 31.24%. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period last year, the firm earned $0.24 EPS. Research analysts predict that Airbnb, Inc. will post 4.92 earnings per share for the current year.

Analyst Ratings Changes Several equities analysts recently issued reports on ABNB shares. Wedbush began coverage on Airbnb in a research report on Thursday, July 16th. They issued a “neutral” rating and a $152.00 target price on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $170.00 price target on shares of Airbnb in a research report on Friday, May 8th. Tigress Financial dropped their price target on Airbnb from $200.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Weiss Ratings raised Airbnb from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, May 12th. Finally, Truist Financial raised their price objective on Airbnb from $129.00 to $134.00 and gave the stock a “hold” rating in a research note on Friday, June 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $159.65.

View Our Latest Research Report on Airbnb

Airbnb Profile (Free Report)

Airbnb, Inc (NASDAQ: ABNB) operates a global online marketplace that connects travelers with hosts offering short-term lodging, unique accommodations and related travel experiences. The company’s core platform enables individuals and professional property managers to list private homes, apartments, single rooms and entire properties, while providing search, booking and payment processing for guests. Airbnb earns revenue primarily through service fees charged to guests and hosts and offers tools to facilitate reservations, communications, and logistics between parties.

Beyond accommodations, Airbnb has expanded its product portfolio to include curated experiences led by local hosts, higher-end offerings such as Airbnb Luxe, and programs aimed at enhancing quality and safety like Airbnb Plus.

Further Reading Five stocks we like better than Airbnb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABNB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Airbnb, Inc. (NASDAQ:ABNB – Free Report).

Receive News & Ratings for Airbnb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Airbnb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Has $8.77 Million Stock Holdings in Intercontinental Exchange Inc. $ICE

NEXT HEADLINE »Amova Asset Management Americas Inc. Increases Holdings in TotalEnergies SE Sponsored ADR $TTE

HomeStock IdeasLong IdeasConsumer Staples Analysis

SummaryDollar General remains a buy, with shares still undervalued around $127 despite a recent rally.DG's recent quarterly results show positive momentum: 1.4% traffic growth and a 2% same-store sales increase.Risks include market saturation, rising competition from Aldi, Walmart, and Amazon, and the threat of grocery delivery eroding DG’s convenience edge.I advise moderate position sizing as DG approaches potential saturation and faces intensifying headwinds. M. Suhail/iStock Editorial via Getty Images

Dollar General (DG) has topped $127, rebounding from a hard crash earlier this year. It’s fair to wonder if the rally is over, but the valuation remains reasonable and the quarterly report some weeks back points

1.3K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of DG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Posted by Defense World Staff on Jul 21st, 2026

California Public Employees Retirement System reduced its holdings in shares of VeriSign, Inc. (NASDAQ:VRSN – Free Report) by 7.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 202,628 shares of the information services provider’s stock after selling 15,659 shares during the period. California Public Employees Retirement System owned approximately 0.22% of VeriSign worth $50,325,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. DV Equities LLC acquired a new stake in shares of VeriSign during the fourth quarter worth about $28,000. Sunbelt Securities Inc. increased its position in VeriSign by 429.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 127 shares of the information services provider’s stock valued at $36,000 after acquiring an additional 103 shares during the period. Advisors Asset Management Inc. increased its position in VeriSign by 25.3% in the 1st quarter. Advisors Asset Management Inc. now owns 198 shares of the information services provider’s stock valued at $50,000 after acquiring an additional 40 shares during the period. Activest Wealth Management raised its stake in VeriSign by 788.0% during the 4th quarter. Activest Wealth Management now owns 222 shares of the information services provider’s stock valued at $54,000 after acquiring an additional 197 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in VeriSign by 120.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 234 shares of the information services provider’s stock valued at $57,000 after acquiring an additional 128 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets In other news, CEO D James Bidzos sold 3,300 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $266.09, for a total value of $878,097.00. Following the completion of the transaction, the chief executive officer owned 422,839 shares in the company, valued at $112,513,229.51. This trade represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas C. Indelicarto sold 250 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $269.23, for a total transaction of $67,307.50. Following the completion of the transaction, the executive vice president owned 36,051 shares of the company’s stock, valued at $9,706,010.73. This represents a 0.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 26,300 shares of company stock valued at $7,125,942. 0.56% of the stock is owned by corporate insiders.

VeriSign Trading Down 0.0% Shares of VRSN opened at $277.61 on Tuesday. VeriSign, Inc. has a twelve month low of $208.86 and a twelve month high of $312.48. The stock’s 50 day moving average is $278.56 and its two-hundred day moving average is $258.66. The firm has a market capitalization of $25.26 billion, a PE ratio of 30.68 and a beta of 0.71.

VeriSign (NASDAQ:VRSN – Get Free Report) last released its earnings results on Thursday, April 23rd. The information services provider reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.04. VeriSign had a negative return on equity of 39.98% and a net margin of 49.95%.The company had revenue of $428.90 million for the quarter, compared to analysts’ expectations of $424.50 million. During the same quarter in the previous year, the firm posted $2.10 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. On average, sell-side analysts predict that VeriSign, Inc. will post 9.45 EPS for the current year.

Analysts Set New Price Targets Several brokerages have weighed in on VRSN. JPMorgan Chase & Co. lifted their target price on VeriSign from $285.00 to $308.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Robert W. Baird upped their price target on VeriSign from $305.00 to $355.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Citigroup increased their price target on VeriSign from $295.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Weiss Ratings reiterated a “buy (b-)” rating on shares of VeriSign in a research report on Wednesday, June 24th. Finally, Wedbush assumed coverage on shares of VeriSign in a research note on Thursday, July 16th. They issued an “outperform” rating and a $318.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $325.25.

View Our Latest Stock Report on VeriSign

About VeriSign (Free Report)

VeriSign, Inc (NASDAQ: VRSN) is an internet infrastructure company that operates critical components of the global Domain Name System (DNS) and provides cybersecurity-related services. The company is best known as the authoritative registry operator for the .com and .net top-level domains, maintaining the central databases and zone files that enable domain name resolution for millions of websites. VeriSign’s registry role is performed under contractual agreements with Internet Corporation for Assigned Names and Numbers (ICANN) and involves high-availability, highly secure operations to support continuous internet connectivity.

In addition to its registry business, VeriSign offers a suite of services designed to protect and accelerate DNS and internet traffic for enterprises and service providers.

Further Reading Five stocks we like better than VeriSign The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for VeriSign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VeriSign and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECummins Inc. $CMI Stock Holdings Increased by Bessemer Group Inc.

NEXT HEADLINE »Bessemer Group Inc. Acquires 39,227 Shares of iShares MSCI ACWI ex U.S. ETF $ACWX

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden raised its stake in shares of Palantir Technologies Inc. (NASDAQ:PLTR – Free Report) by 5.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 407,700 shares of the company’s stock after purchasing an additional 22,663 shares during the period. Palantir Technologies accounts for 0.7% of Andra AP fonden’s holdings, making the stock its 19th biggest position. Andra AP fonden’s holdings in Palantir Technologies were worth $59,638,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Wilkerson Advisory Group LLC increased its stake in shares of Palantir Technologies by 247.5% during the first quarter. Wilkerson Advisory Group LLC now owns 1,032 shares of the company’s stock worth $151,000 after purchasing an additional 735 shares in the last quarter. Dale Q Rice Investment Management Ltd lifted its stake in Palantir Technologies by 15.8% in the 1st quarter. Dale Q Rice Investment Management Ltd now owns 5,783 shares of the company’s stock valued at $846,000 after buying an additional 789 shares in the last quarter. Glenview Trust Co lifted its stake in Palantir Technologies by 24.1% in the 1st quarter. Glenview Trust Co now owns 6,059 shares of the company’s stock valued at $886,000 after buying an additional 1,177 shares in the last quarter. Summit Global Investments increased its stake in Palantir Technologies by 110.7% during the 1st quarter. Summit Global Investments now owns 32,355 shares of the company’s stock worth $4,733,000 after buying an additional 17,001 shares in the last quarter. Finally, Convergence Investment Partners LLC increased its stake in Palantir Technologies by 438.9% during the 1st quarter. Convergence Investment Partners LLC now owns 9,436 shares of the company’s stock worth $1,380,000 after buying an additional 7,685 shares in the last quarter. Institutional investors and hedge funds own 45.65% of the company’s stock.

Analyst Ratings Changes PLTR has been the subject of a number of research analyst reports. Rosenblatt Securities reissued a “buy” rating and set a $225.00 target price on shares of Palantir Technologies in a report on Friday, June 5th. President Capital upgraded Palantir Technologies from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $25.50 to $133.00 in a research report on Monday, June 29th. BTIG Research lowered Palantir Technologies to a “neutral” rating in a report on Tuesday, June 16th. Zacks Research raised shares of Palantir Technologies from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Benchmark lowered shares of Palantir Technologies to a “hold” rating in a report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $190.85.

View Our Latest Analysis on PLTR

Insider Activity In other news, Director Lauren Elaina Friedman Stat sold 1,598 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $160.00, for a total value of $255,680.00. Following the completion of the sale, the director owned 55,022 shares of the company’s stock, valued at $8,803,520. This represents a 2.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shyam Sankar sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $130.00, for a total transaction of $4,550,000.00. Following the sale, the insider owned 642,786 shares of the company’s stock, valued at $83,562,180. This represents a 5.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,112,270 shares of company stock valued at $150,247,785 in the last quarter. Insiders own 9.53% of the company’s stock.

Palantir Technologies Price Performance PLTR stock opened at $134.85 on Tuesday. Palantir Technologies Inc. has a 1 year low of $106.37 and a 1 year high of $207.52. The firm has a market capitalization of $323.28 billion, a PE ratio of 151.52, a price-to-earnings-growth ratio of 2.12 and a beta of 1.56. The business has a 50 day simple moving average of $132.16 and a 200-day simple moving average of $143.69.

Palantir Technologies (NASDAQ:PLTR – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.05. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.54 billion. Palantir Technologies had a return on equity of 28.34% and a net margin of 43.67%.The firm’s revenue was up 84.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.13 earnings per share. On average, equities research analysts expect that Palantir Technologies Inc. will post 1.17 EPS for the current year.

Key Stories Impacting Palantir Technologies Here are the key news stories impacting Palantir Technologies this week:

Positive Sentiment: Several articles argue Palantir’s long-term growth case remains intact, pointing to its expanding AI software footprint and the strength of its AIP platform. Palantir: The Stock Is Richly Valued With a Forward P/S Multiple of Over 40x, but Is the Growth Story Still Worth Buying Into? Positive Sentiment: Commentary from top investors and market watchers says Palantir’s business momentum and product expansion could support further gains despite the stock’s premium valuation. It’s Not Crazy, Says Top Investor About Palantir Stock Positive Sentiment: Another piece says Palantir keeps defying skeptics with a string of earnings beats and a raised outlook, reinforcing the idea that fundamentals are still improving. Predicition: Palantir Defies Doubters. Here’s Our New Price Target Neutral Sentiment: Palantir is also being widely searched and discussed, which shows elevated investor interest but does not by itself change the outlook. Neutral Sentiment: Several articles revisit the stock’s big run from its IPO and its recent pullback, keeping focus on valuation and volatility rather than any new company-specific catalyst. Palantir Technologies Profile (Free Report)

Palantir Technologies is a software company that develops data integration, analytics and operational decision-making platforms for government and commercial customers. Founded in 2003 by a team that included Alex Karp and Peter Thiel, Palantir has grown into a provider of enterprise-scale software designed to help organizations integrate disparate data sources, build analytic models and drive operational workflows. The company went public in 2020 and continues to position its products around large, complex data projects where security, provenance and real-time collaboration are important.

Palantir’s product portfolio centers on a small number of core platforms.

Featured Stories Five stocks we like better than Palantir Technologies The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding PLTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palantir Technologies Inc. (NASDAQ:PLTR – Free Report).

Receive News & Ratings for Palantir Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palantir Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEApplied Materials, Inc. $AMAT Shares Sold by Andra AP fonden

NEXT HEADLINE »Andra AP fonden Grows Position in Parker-Hannifin Corporation $PH

Shares of Palantir Technologies (PLTR 0.77%) have shed 20% of their value in 2026 as of this writing, driven mainly by the broader weakness in artificial intelligence (AI) stocks and the company's expensive valuation.

However, Palantir stock could get a big shot in the arm when the company releases its second-quarter results on Aug. 3. Let's see why that's likely to be the case.

Image source: The Motley Fool.

Software stocks are winning back investor confidence This has been a difficult year for software stocks. The sector has taken a beating amid fears that the advent of agentic AI could upend the traditional software industry. However, software stocks seem to be gaining popularity among investors once again.

Today's Change

(

-0.77

%) $

-1.04

Current Price

$

133.81

The iShares Expanded Tech-Software Sector ETF, an exchange-traded fund that invests in North American software, media, and services companies, has appreciated 9% over the past three months. Even Palantir stock has recovered 26% from the 52-week low it reached on June 25.

This turnaround in software stocks can be attributed to a change in perception, as investors now believe that integrating AI tools can be beneficial for software-oriented businesses. Palantir is a classic example of how offering AI solutions to customers can significantly accelerate a company's growth. The company's growth rate has picked up impressively since the launch of its Artificial Intelligence Platform (AIP) just over three years ago.

Data by YCharts

Palantir's customers have seen significant improvements in productivity by deploying its AI tools, which is why they have been spending more on its offerings. This is why I believe Palantir could crush Wall Street's expectations once again on Aug. 3 and raise its guidance.

Palantir's potential beat-and-raise quarterly report could give the stock a big boost Palantir's earnings have exceeded Wall Street's expectations in each of the last four quarters. That trend is likely to continue, as the company is getting more business than it can fulfill. This is evidenced by Palantir recording new contracts worth $2.41 billion in Q1, up 61% from the year-ago period. That was higher than the $1.63 billion revenue the company clocked during the quarter.

Palantir's remaining deal value (RDV), which is the total value of contracts yet to be fulfilled, increased by 98% year over year to $11.8 billion, exceeding the 85% increase in revenue. The strong deal momentum and the addition of new customers encouraged Palantir to raise its guidance. A similar situation could unfold on Aug. 3, and this time, the market could reward Palantir for its improving growth trajectory.

After all, Palantir is among the leading players in the fast-growing AI software market, which is expected to see a whopping 12x increase in revenue between 2024 and 2034, according to a third-party estimate. Palantir's addressable opportunity could jump to $237 billion in 2034, indicating that it is at the beginning of a terrific growth curve that will help justify its valuation.

A strong set of results and guidance next month should reinforce Palantir's growth prospects and further enhance investor confidence in the stock. For all these reasons, I believe the recent rally in Palantir could continue, and the software specialist may even see a parabolic move in its stock price.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden cut its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 51.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 332,662 shares of the biopharmaceutical company’s stock after selling 348,938 shares during the period. Andra AP fonden’s holdings in Bristol Myers Squibb were worth $20,176,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of BMY. waypoint wealth counsel bought a new position in Bristol Myers Squibb in the fourth quarter valued at about $1,194,000. Life Cycle Investment Partners Ltd acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $34,406,000. Axxcess Wealth Management LLC raised its holdings in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares during the last quarter. Daytona Street Capital LLC acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $1,362,000. Finally, Pensionfund Sabic acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $1,845,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.7% Shares of Bristol Myers Squibb stock opened at $60.30 on Tuesday. The stock’s 50-day moving average is $57.11 and its 200 day moving average is $57.85. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm has a market cap of $123.14 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current year.

Bristol Myers Squibb Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Analyst Ratings Changes Several equities analysts have issued reports on the stock. Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Bank of America cut their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $61.25.

View Our Latest Report on BMY

More Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon Bristol Myers Squibb Company Profile (Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

See Also Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECorning Incorporated $GLW Shares Purchased by Andra AP fonden

NEXT HEADLINE »Andra AP fonden Decreases Stock Holdings in Garmin Ltd. $GRMN

Posted by Defense World Staff on Jul 21st, 2026

California Public Employees Retirement System raised its position in Albemarle Corporation (NYSE:ALB – Free Report) by 19.0% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 271,555 shares of the specialty chemicals company’s stock after purchasing an additional 43,283 shares during the period. California Public Employees Retirement System owned 0.23% of Albemarle worth $48,752,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ALB. MH & Associates Securities Management Corp ADV purchased a new position in shares of Albemarle in the fourth quarter worth about $26,000. BOKF NA boosted its position in Albemarle by 5,771.4% during the third quarter. BOKF NA now owns 411 shares of the specialty chemicals company’s stock worth $33,000 after acquiring an additional 404 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in Albemarle during the 4th quarter valued at about $34,000. EverSource Wealth Advisors LLC grew its stake in Albemarle by 536.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company’s stock valued at $36,000 after acquiring an additional 483 shares in the last quarter. Finally, Torren Management LLC acquired a new stake in Albemarle in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 92.87% of the company’s stock.

Albemarle Stock Performance NYSE:ALB opened at $118.01 on Tuesday. Albemarle Corporation has a fifty-two week low of $64.95 and a fifty-two week high of $221.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.21 and a current ratio of 2.07. The company has a 50 day moving average price of $154.62 and a 200 day moving average price of $168.12. The stock has a market capitalization of $13.92 billion, a P/E ratio of -34.61 and a beta of 1.34.

Albemarle (NYSE:ALB – Get Free Report) last announced its earnings results on Wednesday, May 6th. The specialty chemicals company reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $1.71. Albemarle had a positive return on equity of 5.22% and a negative net margin of 5.00%.The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.34 billion. During the same quarter in the previous year, the company earned ($0.18) earnings per share. The firm’s quarterly revenue was up 32.7% compared to the same quarter last year. Equities research analysts forecast that Albemarle Corporation will post 13.07 EPS for the current year.

Albemarle Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Investors of record on Friday, June 12th were issued a $0.405 dividend. This represents a $1.62 annualized dividend and a dividend yield of 1.4%. The ex-dividend date was Friday, June 12th. Albemarle’s payout ratio is currently -47.51%.

Analyst Ratings Changes ALB has been the topic of a number of research reports. Vertical Research raised shares of Albemarle from a “hold” rating to a “buy” rating and set a $224.00 target price on the stock in a research note on Tuesday, May 26th. Berenberg Bank upped their price target on Albemarle from $153.00 to $192.00 and gave the company a “hold” rating in a research report on Tuesday, June 2nd. Wall Street Zen raised Albemarle from a “buy” rating to a “strong-buy” rating in a report on Monday, July 13th. Morgan Stanley lifted their price objective on Albemarle from $170.00 to $189.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 28th. Finally, Mizuho lowered their price objective on Albemarle from $205.00 to $185.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $199.87.

Check Out Our Latest Stock Analysis on ALB

Insider Transactions at Albemarle In related news, CEO J Kent Masters sold 16,393 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $183.72, for a total transaction of $3,011,721.96. Following the transaction, the chief executive officer owned 87,519 shares of the company’s stock, valued at approximately $16,078,990.68. This represents a 15.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.42% of the company’s stock.

Albemarle Company Profile (Free Report)

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.

Featured Articles Five stocks we like better than Albemarle The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Cuts Stake in Hubbell Inc $HUBB

NEXT HEADLINE »California Public Employees Retirement System Has $49.75 Million Holdings in Church & Dwight Co., Inc. $CHD

Andar Capital Management HK Ltd acquired a new position in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,000 shares of the semiconductor manufacturer’s stock, valued at approximately $1,351,000. Micron Technology comprises 1.2% of Andar Capital Management HK Ltd’s investment portfolio, making the stock its 12th biggest holding.

A number of other large investors also recently added to or reduced their stakes in MU. Resolute Advisors LLC acquired a new position in shares of Micron Technology in the 1st quarter valued at $278,000. MWA Asset Management increased its position in shares of Micron Technology by 105.1% in the 1st quarter. MWA Asset Management now owns 1,487 shares of the semiconductor manufacturer’s stock valued at $502,000 after buying an additional 762 shares in the last quarter. JSF Financial LLC increased its position in shares of Micron Technology by 6.4% in the 1st quarter. JSF Financial LLC now owns 3,332 shares of the semiconductor manufacturer’s stock valued at $1,126,000 after buying an additional 200 shares in the last quarter. Legacy Wealth Managment LLC ID raised its stake in Micron Technology by 54.2% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 572 shares of the semiconductor manufacturer’s stock worth $193,000 after buying an additional 201 shares during the period. Finally, Florida Financial Advisors LLC lifted its holdings in Micron Technology by 22.4% during the first quarter. Florida Financial Advisors LLC now owns 11,457 shares of the semiconductor manufacturer’s stock worth $3,871,000 after acquiring an additional 2,096 shares in the last quarter. 80.84% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Micron Technology Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Micron is being highlighted as a strong AI chip and memory beneficiary, with several bullish articles pointing to durable demand, strong profitability, and attractive valuation after the recent pullback. NVIDIA & Micron: 2 Profitable AI Stocks With Strong Growth Potential Positive Sentiment: Morgan Stanley and other analysts said the selloff in memory stocks created a strong buying opportunity, arguing that data-center memory shortages are still intensifying. The Memory Stock Sell-Off Created a ‘Strong Entry Point,’ Says Morgan Stanley. Investors Are Buying In. Positive Sentiment: Shares of Micron, SanDisk, and Western Digital rebounded as investors rotated back into semiconductor names after last week’s sharp drop in AI-related stocks. Micron Jumps 5%, SanDisk Rises 6%, Western Digital Climbs 4% as Memory Stocks Rebound With Chips Positive Sentiment: A Seeking Alpha upgrade argued Micron’s business model and large backlog could drive EPS accretion and multiple expansion through FY2027. Micron: Berkshire-ification Against The Possible Greenfield Margin Squeeze (Upgrade) Neutral Sentiment: Some coverage noted large institutional call buying and speculative dip-buying in Micron, which can support short-term trading sentiment but does not change the company’s fundamentals. The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence (MU) Neutral Sentiment: Several articles focused on Micron’s broader role in the AI trade and memory shortage, reinforcing that the stock remains highly sensitive to swings in semiconductor sentiment. Micron, Lumentum, Sweetgreen, AMC, Domino’s, and More Stocks That Explain Today’s Market Negative Sentiment: Michael Burry’s short position and warning that Micron is “cyclical like no other” added caution around the stock’s valuation and the risk of a deeper AI-chip correction. Claude AI Says Michael Burry’s Micron (MU) Warning “Deserves Respect” Negative Sentiment: Bearish commentary also warned that semiconductor and technology stocks could still face another leg down if the recent AI trade unwind continues. Expect a 75% technology stocks wipeout, warns strategist Negative Sentiment: Micron has also been under pressure recently after SK Hynix’s memory-price warning sparked debate over how long tight supply can last, contributing to the prior selloff. Micron Stock Set to Snap Losing Streak After SK Hynix Memory Price Warning Analysts Set New Price Targets Several equities analysts have recently weighed in on the company. Citigroup lifted their price objective on Micron Technology from $1,200.00 to $1,400.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Sanford C. Bernstein set a $1,300.00 price target on shares of Micron Technology in a report on Monday, June 22nd. Mizuho increased their price objective on shares of Micron Technology from $1,150.00 to $1,375.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. TD Cowen restated a “buy” rating on shares of Micron Technology in a report on Friday, July 10th. Finally, Melius Research began coverage on shares of Micron Technology in a research report on Monday, April 27th. They issued a “buy” rating and a $700.00 price objective on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, thirty have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Micron Technology has an average rating of “Buy” and a consensus price target of $1,268.93.

Check Out Our Latest Stock Report on Micron Technology

Insider Activity at Micron Technology In other Micron Technology news, EVP April S. Arnzen sold 40,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $1,083.94, for a total value of $43,357,600.00. Following the transaction, the executive vice president directly owned 85,737 shares in the company, valued at $92,933,763.78. The trade was a 31.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lynn A. Dugle sold 1,300 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $1,150.43, for a total transaction of $1,495,559.00. Following the completion of the transaction, the director directly owned 17,728 shares in the company, valued at $20,394,823.04. The trade was a 6.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 163,300 shares of company stock valued at $152,667,204. 0.24% of the stock is owned by company insiders.

Micron Technology Price Performance Shares of MU opened at $865.46 on Tuesday. The company has a current ratio of 3.42, a quick ratio of 2.98 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $950.86 and its 200 day simple moving average is $606.14. Micron Technology, Inc. has a 1-year low of $103.38 and a 1-year high of $1,255.00. The company has a market cap of $977.44 billion, a price-to-earnings ratio of 19.59 and a beta of 2.14.

Micron Technology (NASDAQ:MU – Get Free Report) last announced its quarterly earnings results on Wednesday, June 24th. The semiconductor manufacturer reported $25.11 EPS for the quarter, beating analysts’ consensus estimates of $21.39 by $3.72. Micron Technology had a net margin of 55.91% and a return on equity of 71.13%. The firm had revenue of $41.46 billion during the quarter, compared to analysts’ expectations of $35.91 billion. During the same quarter last year, the company posted $1.91 earnings per share. The company’s revenue for the quarter was up 345.8% compared to the same quarter last year. Micron Technology has set its Q4 2026 guidance at 30.000-32.000 EPS. On average, research analysts forecast that Micron Technology, Inc. will post 72.93 earnings per share for the current fiscal year.

Micron Technology Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 21st. Investors of record on Monday, July 6th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Monday, July 6th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.1%. Micron Technology’s payout ratio is presently 1.36%.

Micron Technology Company Profile (Free Report)

Micron Technology, Inc is a global semiconductor company that designs and manufactures memory and storage solutions. Its product portfolio includes dynamic random-access memory (DRAM), NAND flash memory, solid-state drives (SSDs), memory modules and embedded memory solutions for a wide range of computing and electronic devices. Micron supplies components used in data centers, enterprise and cloud infrastructure, client computing, mobile devices, automotive systems and industrial applications, and also markets consumer-facing products under the Crucial brand.

Founded in 1978 and headquartered in Boise, Idaho, Micron has grown into an international manufacturer with research, development and production facilities across multiple regions.

Featured Articles Five stocks we like better than Micron Technology The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding MU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Micron Technology, Inc. (NASDAQ:MU – Free Report).

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 139.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 50,050 shares of the medical equipment provider’s stock after purchasing an additional 29,168 shares during the period. Andra AP fonden’s holdings in Intuitive Surgical were worth $23,073,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ISRG. Draper Asset Management LLC boosted its stake in shares of Intuitive Surgical by 41.9% in the fourth quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock valued at $2,848,000 after buying an additional 1,485 shares during the period. Deutsche Bank AG lifted its holdings in shares of Intuitive Surgical by 9.6% in the fourth quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider’s stock worth $862,108,000 after acquiring an additional 132,966 shares during the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of Intuitive Surgical by 29.3% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 71,077 shares of the medical equipment provider’s stock worth $40,255,000 after buying an additional 16,119 shares during the last quarter. Procyon Advisors LLC grew its position in Intuitive Surgical by 787.8% during the 4th quarter. Procyon Advisors LLC now owns 4,794 shares of the medical equipment provider’s stock worth $2,715,000 after acquiring an additional 4,254 shares during the last quarter. Finally, Robinhood Asset Management LLC bought a new stake in Intuitive Surgical during the 4th quarter worth approximately $6,478,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth ISRG has been the subject of several analyst reports. Wall Street Zen upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Raymond James Financial reiterated an “outperform” rating and issued a $483.00 price target (down from $577.00) on shares of Intuitive Surgical in a report on Friday. Wells Fargo & Company reiterated an “overweight” rating and set a $487.00 price objective (down from $654.00) on shares of Intuitive Surgical in a report on Friday. Bank of America decreased their price target on Intuitive Surgical from $520.00 to $515.00 in a report on Friday, June 12th. Finally, Mizuho set a $500.00 target price on shares of Intuitive Surgical and gave the company a “neutral” rating in a report on Wednesday, July 15th. Twenty-one investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $523.46.

Get Our Latest Research Report on ISRG

Intuitive Surgical Trading Up 2.2% Shares of NASDAQ ISRG opened at $353.17 on Tuesday. Intuitive Surgical, Inc. has a 12 month low of $342.10 and a 12 month high of $603.88. The firm has a market capitalization of $125.08 billion, a price-to-earnings ratio of 40.45, a PEG ratio of 2.80 and a beta of 1.46. The business has a 50-day moving average of $413.94 and a 200-day moving average of $465.58.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last announced its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.45% and a return on equity of 17.09%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same period last year, the firm posted $1.81 earnings per share. Intuitive Surgical’s quarterly revenue was up 23.0% on a year-over-year basis. On average, analysts predict that Intuitive Surgical, Inc. will post 8.62 earnings per share for the current year.

Insider Transactions at Intuitive Surgical In related news, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total value of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This represents a 46.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the sale, the executive vice president owned 5,720 shares in the company, valued at $2,426,080.80. The trade was a 6.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,169 shares of company stock valued at $3,059,135 in the last quarter. Insiders own 0.60% of the company’s stock.

Key Headlines Impacting Intuitive Surgical Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Some market commentary argues ISRG’s recent correction may have reset expectations, with oversold technical conditions and improving earnings estimate revisions potentially setting up a near-term rebound. Down 15% in 4 Weeks, Here’s Why You Should You Buy the Dip in Intuitive Surgical (ISRG) Positive Sentiment: Zacks highlighted Intuitive Surgical as a trending stock with strong growth characteristics, saying the company’s fundamentals and growth profile may appeal to investors looking for long-term outperformance. 3 Reasons Growth Investors Will Love Intuitive Surgical (ISRG) Positive Sentiment: Another piece noted investor interest in ISRG remains elevated, suggesting the stock is staying on traders’ radar even after recent weakness. Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It Neutral Sentiment: Commentary focused on whether investors should prioritize Intuitive Surgical’s current robot sales or its longer-term growth opportunity, reinforcing the debate around valuation versus future expansion. What’s More Important For Intuitive Surgical: Today’s Robots Or Tomorrow’s Growth? Negative Sentiment: Several analyst updates were cautious, with firms including Stifel, Sanford C. Bernstein, and Citigroup lowering price targets or expectations, which likely added to the selling pressure on ISRG. Stifel Nicolaus Lowers Intuitive Surgical (NASDAQ:ISRG) Price Target to $550.00 About Intuitive Surgical (Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

See Also Five stocks we like better than Intuitive Surgical The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report).

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Boosts Stake in DoorDash, Inc. $DASH

For investors who have spent years focusing on dilution, debt and meme-stock volatility, that may represent the company’s most meaningful shift yet.

Record EBITDA, Stronger Cash FlowAMC reported record second-quarter adjusted EBITDA of $321.4 million, up 70% year-over-year, on record revenue of nearly $1.6 billion. More importantly, the company converted that operating momentum into $190.1 million of free cash flow during the quarter, giving management confidence that consistent annual cash generation is now within reach.

“We’re within sight of being cash flow positive, not for a quarter, but for a year,” Aron said during the earnings call. He later acknowledged the company is “not quite at the promised land yet… but we’re ever so close.”

The comments suggest AMC’s investment narrative is beginning to evolve. While the company still depends on a healthy theatrical release slate, management increasingly believes years of cost controls, premium-format expansion and higher spending per guest have structurally improved its earnings power.

CFO Sean Goodman noted AMC generated more revenue and nearly 40% more adjusted EBITDA than it did in the second quarter of 2019 despite attendance remaining well below pre-pandemic levels.

Debt Reduction Creates A Financial FlywheelThe turnaround isn’t limited to operating performance. Aron said AMC has reduced debt by approximately $1.7 billion since the end of 2020, while Goodman said the company now expects no significant debt maturities before 2029 following recent refinancing efforts. Those actions are also lowering borrowing costs, with management expecting meaningful reductions in annual interest expense as leverage ratios continue to improve.

That creates what could become a virtuous financial cycle. Higher EBITDA improves leverage ratios, lower leverage reduces interest costs, and lower interest expense further reduces the box office threshold needed for AMC to generate positive free cash flow over a full year.

“If interest rates go down, interest expense goes down, and that means that the breakeven box office level goes down as well,” Aron said.

Why Investors Should Watch The Next Few QuartersAMC isn’t declaring victory just yet, but the conversation has clearly changed.

For years, investors judged the company by how much cash it could raise and how long it could survive. Following its strongest operating quarter on record, management wants investors to judge it by how much cash it can consistently generate instead.

If upcoming blockbuster releases help sustain box office momentum, the next milestone may not be another record EBITDA quarter—it could be AMC proving that its long-promised transition from a liquidity story to a sustainable cash-flow story is finally complete.

Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

BlackBerry is rated a speculative Buy, with asymmetric upside potential driven by QNX and the Alloy Kore middleware opportunity. QNX's ~$950m royalty backlog and record development license revenue signal robust forward growth, though much of it is long-dated. Valuation sensitivity centers on QNX; Alloy Kore could multiply revenue from existing customers and expand into non-automotive markets.

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden cut its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,366 shares of the medical research company’s stock after selling 11,734 shares during the quarter. Andra AP fonden’s holdings in Amgen were worth $17,721,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Anfield Capital Management LLC boosted its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Tower View Wealth Management LLC raised its holdings in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the last quarter. Manning & Napier Advisors LLC raised its holdings in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new stake in Amgen during the 4th quarter worth approximately $33,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.6% Amgen stock opened at $364.17 on Tuesday. The firm has a 50 day moving average price of $348.38 and a 200-day moving average price of $350.78. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The company has a market capitalization of $196.55 billion, a P/E ratio of 25.34, a P/E/G ratio of 3.71 and a beta of 0.41.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the firm posted $4.90 EPS. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.31 EPS for the current year.

Analysts Set New Price Targets A number of equities research analysts have commented on AMGN shares. Daiwa Securities Group reduced their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Argus decreased their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. UBS Group increased their target price on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Truist Financial raised their price target on shares of Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. Finally, Guggenheim lifted their price objective on shares of Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $356.62.

Get Our Latest Report on AMGN

Insider Activity at Amgen In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by corporate insiders.

Amgen Company Profile (Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Recommended Stories Five stocks we like better than Amgen The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArbor Trust Wealth Advisors LLC Decreases Stock Position in Apple Inc. $AAPL

NEXT HEADLINE »Assetmark Inc. Purchases 49,925 Shares of Alphabet Inc. $GOOG

Building one home on each empty lot listed for sale on Zillow would reduce the national housing deficit to 4.44 million homes

A housing shortage of 4.7 million homes is the key driver of America's housing affordability crisis. 300,242 empty lots smaller than 5 acres were listed for sale on Zillow in June 2026, representing 17.4% of all for-sale listings. Building one home on each of those lots would reduce America's housing deficit by 6.3%. Zillow is participating in a federal tech sprint to find ways to reduce friction for rural buyers looking to build on an empty lot. , /PRNewswire/ -- America's housing affordability crisis is largely a supply problem, with the country currently being 4.7 million homes short of what is needed. If one home were built on every empty lot listed for sale, that shortage would shrink by more than 6%, new Zillow® research finds.

More than 300,000 empty lots 5 acres or smaller were listed for sale on Zillow in June, making up 17.4% of all for-sale listings. Building just one home on each of those lots would bring the total housing deficit down to roughly 4.44 million homes, a 6.3% reduction from the latest estimate. The typical lot for sale is 0.57 acres — large enough, in many cases, to support more than one home, meaning the 6.3% figure is conservative.

"The more than 300,000 lots currently listed for sale represent the lowest-hanging fruit in addressing a housing shortage that's two decades in the making," said Kara Ng, senior economist at Zillow. "The challenge is making it feasible to build. Loosening zoning rules, streamlining permitting and expanding access to financing would reduce the cost and uncertainty that hold construction back, turning available lots into much-needed homes. The ROAD to Housing Act is an encouraging sign that policymakers understand what it will take to close the gap, but some of this reform will need to happen at the state and local levels."

Where the empty lots are
The five states with the most empty lots listed are Florida (42,601), Texas (40,907), California (18,508), North Carolina (14,226) and Georgia (10,334). In states such as North Dakota, South Dakota and Alaska, empty lots make up more than one-third of all for-sale listings — 45.9%, 38.7% and 34.6%, respectively.

Rural markets have the highest concentration of empty lots, at 25.3% of all for-sale listings, compared to 13.6% in the suburbs and 9% in urban areas. Rural lots are also the least expensive on a per-acre basis with a median of roughly $75,000 per acre, compared to more than $181,000 per acre in suburban areas and about $500,000 per acre for urban lots.

Clearing the path to more homes
Closing a gap this large requires solutions that address the problem from multiple angles. Zillow advocates for measures that make it easier and less expensive to build, such as modernizing zoning to allow more density, streamlining permitting, expanding financing options and expanding access to lower-cost housing options like manufactured homes. Manufactured homes are particularly well-suited to helping close this gap, as they can be built faster and at a fraction of the cost of traditional, site-built construction. Recent legislation, including the 21st Century ROAD to Housing Act, is already addressing some of those barriers.

One hurdle for buyers interested in these lots is navigating a fragmented process — finding land, selecting a home type and securing financing are typically three separate and confusing steps. Zillow is working to change that through innovative solutions. This summer, the company has been participating in a 12-week federal tech sprint with the U.S. Census Bureau's Opportunity Project; its focus is on finding ways to increase access to small-dollar housing loans in rural communities. Zillow is exploring ways to reduce frictions for consumers who are interested in purchasing and building on an empty lot.

State

Empty lots
listed for sale
(June 2026)

Share of
listings that
were empty
lots (June
2026)

Median
acreage

Median price

United States

300,242

17.4 %

0.57

$79,000

Alabama

7,651

20.2 %

0.75

$70,900

Alaska

1,131

34.6 %

1.24

$90,000

Arizona

8,131

16.2 %

1.03

$90,000

Arkansas

6,621

25.1 %

0.50

$38,000

California

18,508

16.8 %

0.63

$73,000

Colorado

6,284

13.9 %

0.97

$125,000

Connecticut

425

7.6 %

1.26

$150,000

Delaware

462

9.2 %

0.75

$252,500

Florida

42,601

18.1 %

0.26

$49,000

Georgia

10,341

14.1 %

1.00

$84,900

Hawaii

1,411

16.9 %

1.00

$100,000

Idaho

3,175

19.3 %

0.98

$215,000

Illinois

6,668

22.2 %

0.43

$49,990

Indiana

4,124

15.0 %

0.43

$69,900

Iowa

4,145

25.0 %

0.39

$85,900

Kansas

2,018

19.4 %

0.44

$58,500

Kentucky

4,370

20.1 %

0.87

$49,900

Louisiana

9,159

29.5 %

0.50

$68,000

Maine

1,231

15.7 %

1.80

$94,900

Maryland

1,676

8.7 %

0.75

$125,000

Massachusetts

846

6.2 %

1.17

$225,000

Michigan

8,597

21.5 %

0.59

$55,000

Minnesota

4,962

19.3 %

0.58

$85,000

Mississippi

4,273

24.7 %

0.69

$53,625

Missouri

5,607

18.6 %

0.50

$60,000

Montana

2,395

21.3 %

0.83

$195,000

Nebraska

2,773

30.4 %

0.27

$79,941

Nevada

2,869

15.5 %

0.72

$69,000

New Hampshire

573

12.6 %

1.23

$129,900

New Jersey

1,352

6.5 %

0.49

$209,950

New Mexico

4,293

30.3 %

1.00

$50,000

New York

3,554

8.1 %

0.78

$99,900

North Carolina

14,226

18.2 %

1.02

$79,900

North Dakota

2,023

45.9 %

0.40

$70,000

Ohio

4,313

13.0 %

0.46

$74,900

Oklahoma

5,723

19.9 %

0.84

$59,900

Oregon

3,745

16.1 %

0.51

$159,000

Pennsylvania

6,511

18.3 %

0.38

$49,299

Rhode Island

159

9.0 %

0.86

$325,000

South Carolina

5,547

12.2 %

0.77

$95,000

South Dakota

2,466

38.7 %

0.50

$100,000

Tennessee

9,748

17.9 %

0.85

$74,900

Texas

40,907

16.2 %

0.52

$97,000

Utah

3,553

15.7 %

0.67

$283,860

Vermont

382

11.7 %

1.70

$123,000

Virginia

4,843

14.9 %

1.00

$74,500

Washington

5,563

13.9 %

0.50

$180,000

West Virginia

1,685

26.2 %

0.94

$41,700

Wisconsin

5,372

23.8 %

0.64

$84,900

Wyoming

1,167

24.4 %

0.54

$110,000

About Zillow Group
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.

As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so they can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.

Zillow's ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.

Zillow Group's affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime®, dotloop® and Zillow® Closing.

All marks herein are owned by MFTB Holdco, Inc., a Zillow affiliate. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org). © 2026 MFTB Holdco, Inc., a Zillow affiliate.

(ZFIN)

SOURCE Zillow

Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Zillow Group, Inc. (NASDAQ: Z) (NASDAQ: ZG).

What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Zillow Group, Inc. (NASDAQ: Z) (NASDAQ: ZG) shares prior to February 11, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/zillow-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more.

What Is Alleged? It is alleged in a recently filed federal securities fraud class action complain that Zillow Group, Inc. (NASDAQ: Z) (NASDAQ: ZG), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What Can You Do Now? If you purchased Zillow Group, Inc. (NASDAQ: Z) (NASDAQ: ZG) shares prior to February 11, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/zillow-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

#Zillow #Z #ZG $Z $ZG

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305939

Source: Grabar Law Office

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

21.7.2026 15:49, BAACSG

Průmyslově-technologická skupina CSG oznámila záměr vybudovat v americkém Wisconsinu kapacity pro sériovou výrobu proudových motorů pro drony a bezpilotní prostředky. Výrobu zajistí nová společnost Firecrest Aerospace, což je společný podnik firem CSG USA a AviaNera Technologies ze skupiny CSG.

Společnost plánuje ve Stevens Point vybudovat pokročilé výrobní kapacity pro proudové a dvouproudové motory. Projekt počítá s počáteční investicí až 15 mil. USD a bude realizován v několika fázích, přičemž plný náběh sériové výroby s kapacitou až několika tisíc motorů ročně se očekává v roce 2027.

„Bezpilotní systémy budou zásadně ovlivňovat budoucnost obranného průmyslu i podobu moderních vojenských operací. CSG proto v této oblasti buduje vlastní dlouhodobé kompetence – od pohonných jednotek přes další klíčové subsystémy až po schopnost sériové výroby. AviaNera potvrzuje naše ambice stát se významným mezinárodním hráčem v segmentu technologií pro bezpilotní prostředky a projekt Firecrest Aerospace ve Wisconsinu je toho důležitou součástí,“ uvedl Michal Strnad, CEO a předseda představenstva CSG.

Akcie CSG Akcie CSG (BAACSG) dnes na pražské burze rostou o 1,48 % na 349,1 Kč, na RM-SYSTÉMu pak posilují o 1,99 % na 349 Kč.

Zdroj: CSG

Michal Šnobl
Fio banka, a.s.
Prohlášení

Související odkazy CSG: Deutsche Bank snižuje cílovou cenu z 30 EUR na 25 EUR se stávajícím doporučením „buy“ CSG zahájila výstavbu muničního komplexu pro americkou armádu CSG: Jefferies snižuje cílovou cenu z 30 EUR na 25 EUR se stálým doporučením „Buy“ CSG dokončila transfer technologie výroby střelného prachu do polské společnosti MESKO CSG oznámila založení nové americké dceřiné společnosti

Posted by Defense World Staff on Jul 21st, 2026

Assetmark Inc. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,316 shares of the biopharmaceutical company’s stock after purchasing an additional 1,036 shares during the period. Assetmark Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,516,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $1,012,296,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 8,620.0% in the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock valued at $512,881,000 after buying an additional 656,845 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 528.7% in the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance Shares of REGN stock opened at $672.15 on Tuesday. The company has a market capitalization of $71.06 billion, a P/E ratio of 16.38, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The company’s 50 day moving average price is $640.18 and its two-hundred day moving average price is $717.26.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insiders Place Their Bets In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In A number of research analysts have commented on the company. HSBC decreased their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Royal Bank Of Canada decreased their price target on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Finally, Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $787.67.

Read Our Latest Stock Analysis on Regeneron Pharmaceuticals

Key Stories Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat About Regeneron Pharmaceuticals (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Read More Five stocks we like better than Regeneron Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Has $19.06 Million Stake in Robinhood Markets, Inc. $HOOD

NEXT HEADLINE »Angeles Wealth Management LLC Purchases 3,960 Shares of Alphabet Inc. $GOOG

The macro backdrop appears murky as President Trump sets a 50% tariff on Canadian goods, paired with lasting tensions between the U.S. and Iran pinning pressure on crude oil. Alex Coffey discusses the key points to keep in mind and how it affects Tuesday's trading session.

US-listed shares of Taiwan Semiconductor Manufacturing Co. rose nearly 4% in pre-market trading on Tuesday after a report said the world's largest contract chipmaker has finalized plans to increase chipmaking prices next year.

According to a Nikkei Asia report, TSMC has completed discussions with customers on base-price increases ranging from 5% to 10% for both advanced and mature semiconductor production.

The changes are expected to take effect in 2027 as the company seeks to offset rising manufacturing costs.

The report said TSMC began discussions with customers in June and concluded negotiations this month.

The planned increases would apply across advanced and mature chip production, while some artificial intelligence chip orders could face additional surcharges because of continued demand.

The reported price increases come as TSMC faces higher costs for materials, manufacturing equipment and power while continuing to expand production capacity.

The company recently raised its 2026 capital spending outlook, citing strong AI demand and the increasing cost of expanding manufacturing capacity, including its Arizona operations, where its total investment pipeline now stands at $265 billion.

TSMC manufactures chips for some of the world's largest technology companies, including Nvidia, Apple, Advanced Micro Devices, Qualcomm, Amazon and Alphabet.

The Nikkei report said TSMC delayed the planned price increases until 2027 to give customers time to adjust.

Despite the reported pricing changes, the company reiterated its long-standing approach to customer relationships.

"We don’t suddenly increase our price," Chief Executive Officer C. C. Wei told analysts in July after reporting quarterly earnings. "We earn our value and we make sure that our profit, our gross margin is enough for our long-term sustained expansion, that’s to the benefit of my customers and TSMC also, that’s our philosophy."

TSMC also said in a statement on Tuesday: "Our pricing strategy is strategic, not opportunistic. We will continue to work closely with customers and sell our value to them."

According to the report, TSMC's largest AI customers could see the biggest increases.

Orders for high-performance computing chips beyond previously agreed volumes may carry an additional surcharge of 10% to 15% on top of the base price increases.

As a result, some advanced AI chip orders could see total price increases exceeding 10%.

Advanced manufacturing nodes of 7 nanometers and below accounted for 77% of TSMC's second-quarter revenue, while mature nodes including 12nm, 16nm and 28nm contributed the remaining 23%.

The company continues to expand manufacturing capacity to meet demand for AI chips used in data centers, with customers such as Nvidia seeking faster production to ease supply constraints.

Last week, TSMC reported second-quarter revenue of NT$1.27 trillion ($39.44 billion), ahead of Wall Street estimates of NT$1.26 trillion.

Adjusted earnings per share came in at NT$27.25, exceeding estimates of NT$24.29.

During an interview with CNBC last week, Chief Financial Officer Wendell Huang said TSMC is accelerating the buildout of its Arizona facilities to capitalize on the AI "megatrend."

"We’re seeing this strong-structure, multi-year demand, and we do not plan to leave any food on the table for anybody else," Huang said.

He added that the company's 2-nanometer technology is expected to become a larger revenue driver over the coming quarters.

Item 1 of 3 A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, in New York City, U.S., December 11, 2023 (left) and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly, at Rock Canyon Pharmacy in Provo, Utah, U.S., March 29, 2023. REUTERS/Brendan McDermid/George Frey REFILE - QUALITY REPEAT

[1/3]A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, in New York City, U.S., December 11, 2023 (left) and a box of Mounjaro, a tirzepatide injection drug used for... Purchase Licensing Rights, opens new tab Read more

SummaryCompaniesNovo accuses Lilly of claiming its weight-loss medicines outperform Novo'sDanish drugmaker alleges Lilly violated ad and unfair competition laws in Zepbound and Mounjaro adsEli Lilly not immediately available to commentNovo, Lilly locked in battle to dominate U.S. obesity drug marketLONDON, July 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab sued rival Eli Lilly (LLY.N), opens new tab in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.

The Danish company filed the lawsuit in U.S. District Court in New Jersey, alleging ​Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns ​for obesity drug Zepbound and diabetes treatment Mounjaro.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

Novo alleges Lilly compared the highest approved doses of its ⁠medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.

Indianapolis-based ​Eli Lilly did not immediately respond to a request for comment.

"The ads are maliciously and deceptively false because Lilly knowingly cites ​outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines," Novo wrote in its complaint.

Novo and Lilly are locked in a fierce battle for dominance in the U.S. obesity drug market, which analysts expect to be worth more than $100 billion by 2030.

Novo ​was first to market with weight-loss injection Wegovy, but later lost the lead to Lilly's rival Zepbound. After replacing its CEO ​and issuing multiple profit warnings last year, Novo has landed a counterpunch with oral Wegovy, whose strong demand has held up despite the launch ‌of Lilly's ⁠competing pill.

Novo said it is seeking a court order requiring Lilly to withdraw the advertisements and run a corrective advertising campaign. It added that it plans to seek a preliminary injunction if Lilly does not voluntarily remove the ads.

Novo is also seeking damages, including Lilly's profits that can be attributed to the ads.

Shares of Eli Lilly (LLY.N), opens new tab fell 0.5% to $1141.84 in pre-market U.S. trade, while Copenhagen-listed ​Novo Nordisk (NOVOb.CO), opens new tab shares were down 1.7% ​in afternoon trading.

'INADEQUATE DISCLAIMER' IN ⁠ADSNovo said it sent Lilly a cease-and-desist letter in April after the U.S. approved a 7.2-milligram dose of Wegovy. Lilly did not respond to the letter, Novo's general counsel John Kuckelman told ​Reuters, adding that the company instead inserted what he described as an inadequate disclaimer into the ​advertisements.

Novo says the ⁠scale of Lilly's campaign is massive. The ad campaign has been served up to consumers more than 700 million times just since Lilly modified its ad after Novo's letter in late April.

Kuckelman said Lilly's advertisements compare weight-loss results of about 50 pounds for Zepbound with ⁠about 33 ​pounds for Wegovy, even though no head-to-head trial has compared the highest approved ​doses of the medicines. He said separate late-stage trials of the highest doses showed average weight loss of about 48 pounds for Zepbound and 47 pounds for ​Wegovy.

Reporting by Maggie Fick and Michael Erman; Additional reporting by Jonathan Stempel and Christy Santhosh editing by Caroline Humer, Nia Williams and Susan Fenton

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year award in the Beat Coverage of the Year category. Since November 2023, she has also been participating in Reuters coverage related to the Israel-Hamas war. Previously based in Nairobi and Cairo for Reuters and in Lagos for the Financial Times, Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in South Sudan.

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday.

Shares of Danaher Corp (NYSE:DHR) fell sharply in pre-market trading following second-quarter results.

Danaher posted second-quarter adjusted EPS of $1.94, beating market estimates of $1.83. The company’s sales reached $6.265 billion topping estimates of $6.102 billion.

Danaher shares dipped 10.1% to $180.76 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

CompaniesJuly 21 (Reuters) - Danaher (DHR.N), opens new tab raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm ​trimmed its core revenue growth outlook and reported weaker-than-expected revenue ‌in its biotechnology business.

The results come as conditions are improving for the life sciences tools industry as biotechs and pharmaceutical companies increase spending on research and manufacturing ​programs after a prolonged post-pandemic slowdown.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

However, the outlook is "mixed and not ​consistent with a re-acceleration narrative," RBC Capital Markets analysts ⁠said.

Danaher's results also weighed on peers; Agilent Technologies (A.N), opens new tab fell 1.7% before the bell, while Thermo Fisher Scientific (TMO.N), opens new tab, ​Revvity (RVTY.N), opens new tab and Illumina (ILMN.O), opens new tab declined 2% to 4%.

Danaher lowered the upper end of its ​core revenue growth outlook range for the year to 4% from 6% to reflect the impact of weaker respiratory testing revenue, while maintaining the lower end at 3%.

Revenue ​from its biotechnology unit rose 4% to $1.92 billion, below estimates of $1.97 ​billion, according to data compiled by LSEG.

Danaher said underlying demand for bioprocessing, including equipment and ‌consumables ⁠used to make biologic drugs, remained strong, with orders rising by a mid-teens percentage in the quarter, although customer project timing weighed on revenue.

"Assuming demand is not falling off a cliff this badly and ​this is just a ​push-out issue, ⁠we would think some of the weakness would get bought throughout the day for shares to close ​down," Barclays analysts said.

Danaher expects full-year adjusted per-share ​profit of $8.45 ⁠to $8.60, up from $8.35 to $8.55 previously. Analysts were expecting full-year adjusted profit of $8.45 per share.

The company posted second-quarter profit of $1.94 per share, above analysts' estimates ⁠of $1.83 ​per share. Revenue rose 5.5% to $6.27 billion, ​topping estimates of $6.10 billion.

Life sciences revenue increased 5.5% to $1.88 billion, above estimates of $1.80 billion.

Reporting ​by Sahil Pandey and Mariam Sunny in Bengaluru; Editing by Sahal Muhammed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Silver Mines Ltd (ASX:SVL, OTC:SLVMF, FRA:SWQ) has completed a definitive feasibility study (DFS) for the Bowdens Silver Project in New South Wales, outlining a potential 26-year operation with a pre-tax net present value of A$1.04 billion and silver reserves of 93.5 million ounces.

The updated ore reserve stands at 47.9 million tonnes grading 60.8 g/t silver, 0.36% zinc and 0.26% lead, representing a 30% increase in contained silver and a 46% rise in reserve tonnes compared with the previous estimate.

Silver is expected to generate around 91% of project revenue, reinforcing Bowdens’ position as one of the world’s largest undeveloped, silver-dominant projects. 

Strong project returns The staged development plan carries an estimated initial capital cost of A$455 million.

Using a silver price of US$45 per ounce and an Australian-US dollar exchange rate of 0.70, the full life-of-mine plan is forecast to generate a pre-tax operating margin of A$2.39 billion and an undiscounted pre-tax operating surplus of A$1.94 billion.

The project has a forecast pre-tax internal rate of return of 31.5% and a three-year payback period from the start of production.

At the spot assumptions used in the study — US$61 per ounce silver and an exchange rate of 0.69 — the pre-tax NPV increases to A$2.01 billion and the operating margin rises to A$4.04 billion.

Staged development at Bowdens Stage 1 would process 29.9 million tonnes grading 68 g/t silver for 65.4 million ounces over approximately 16 years, with a low waste-to-ore strip ratio of 1.47:1.

During the first five years, average silver production is forecast at 4.7 million ounces annually, with all-in sustaining costs of A$20.47 per ounce, or US$14.33 per ounce.

A proposed second stage would process a further 18.3 million tonnes and extend the potential operating life to 26 years. The additional filtered tailings infrastructure required for Stage 2 has currently been assessed to pre-feasibility study level.

Across the full mine plan, payable production is estimated at 73.2 million ounces of silver, alongside 46,000 tonnes of zinc and 84,000 tonnes of lead.

Approvals remain the priority Immediate focus remains securing development consent from the NSW Government and Independent Planning Commission.

Following consent, Silver Mines will progress the remaining federal environmental permit and state mining lease approvals.

Advanced engineering work relating to the front-end engineering and design process will also begin, while Silver Mines reviews its biodiversity offset strategy and continues discussions with potential project funding partners.

Managing director Jo Battershill said the DFS marked a significant milestone and demonstrated the project’s potential to deliver long-term employment, government revenue and shareholder returns.

“The completion of the Bowdens DFS is a significant milestone for the company and its shareholders. The Board of Silver Mines would like to extend its appreciation to both the shareholder base for its ongoing patience, and the site team for completing this extensive package of works – while facing significant distractions related to the approval process.

“With the Project’s consent now in the hands of the NSW government and Independent Planning Commission, it is important to focus on the economic benefits that the BSP can bring to the community and investors alike. With the regional coal industry under pressure from decarbonisation of the economy, the benefits of this project to the local community are increasingly important.

“With a potential mine life now anticipated to be more than 25 years, the BSP is expected to deliver generational employment opportunities for more than 200 locals at steady state operations, hand-in-hand with strong financial returns to the state government from taxes and royalties, the local council through the voluntary planning agreement and investors alike.

“We very much look forward to progressing the BSP through into the FEED process and subsequent development.”

About Silver Mines Silver Mines is focused on developing the Bowdens Silver Project, around 26 kilometres east of Mudgee in central New South Wales.

Bowdens is Australia’s largest undeveloped silver deposit and sits within a 2,115-square-kilometre tenement package covering around 80 kilometres of the mineralised Rylstone Volcanics.

The broader district is prospective for further silver-lead-zinc, volcanogenic massive sulphide and copper-gold mineralisation.

Production continues to ramp for U.S. Navy's most advanced maritime radar

, /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, was awarded a $1.8 billion contract extension for SPY-6 radars for the U.S. Navy, building on the initial hardware production and sustainment contract awarded in March 2022. The contract includes options which, if exercised, would bring the cumulative value to $3.3 billion.

"This contract extension reflects the Navy's confidence in our ability to deliver advanced, reliable and scalable radar solutions," said Barbara Borgonovi, president of Naval Power at Raytheon. "Our continued investment and commitment to ramping production will ensure the fleet has the sensing advantage to stay ahead of evolving threats for decades to come."

SPY-6 is now aboard two commissioned U.S. Navy ships and is installed on 11 others, all of which are undergoing various stages of testing. Over the next decade, SPY-6 is expected to be deployed on more than 50 U.S. Navy ships, giving the fleet unmatched sensing capability and multi-mission readiness to stay ahead of evolving threats.

Raytheon's SPY-6 family of radars are built on more than a decade of design, testing and manufacturing experience and have been validated by successful performance at sea. The company has invested more than $800 million to modernize its radar manufacturing facilities and expand production capacity. With these upgrades, Raytheon is positioned to double SPY-6 output by 2028, helping ensure long-term availability and lowering cost for the Navy.

Raytheon is significantly expanding its engineering workforce in Andover to support this critical program. Opportunities are available for emerging talent, experienced professionals, and veterans. Discover open roles on our website and apply today.

About Raytheon
Raytheon, an RTX business, is a leading provider of defense solutions to help the U.S. government, our allies and partners defend their national sovereignty and ensure their security. For more than 100 years, Raytheon has developed new technologies and enhanced existing capabilities in integrated air and missile defense, smart weapons, missiles, advanced sensors and radars, interceptors, space-based systems, hypersonics and missile defense across land, air, sea and space.

About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.

For questions or to schedule an interview, please contact [email protected]. 

SOURCE RTX

With Texas Instruments (NASDAQ:TXN | TXN Price Prediction) and ServiceNow (NYSE:NOW) both reporting Q2 2026 results after market close on Wednesday, July 22, 2026, the question for investors is simple: which name is Wall Street actually leaning into ahead of the same-session report?

Disclosure Under Scrutiny: Whether Intuit's TurboTax Risk Disclosures Adequately Addressed Competitive Risks and Pricing Pressures Under SEC Regulation S-K Disclosure Under Scrutiny: Whether Intuit's TurboTax Risk Disclosures Adequately Addressed Competitive Risks and Pricing Pressures Under SEC Regulation S-K